Lionco Pharm Grp Co Ltd (SHG:603669) — Market Cap & Net Worth
Market Cap & Net Worth: Lionco Pharm Grp Co Ltd (603669)
Lionco Pharm Grp Co Ltd (SHG:603669) has a market capitalization of $561.83 Million (CN¥3.84 Billion) as of August 1, 2026. Listed on the SHG stock exchange, this China-based company holds position #11448 globally and #3174 in its home market, demonstrating a 1.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lionco Pharm Grp Co Ltd's stock price CN¥5.39 by its total outstanding shares 712330243 (712.33 Million). See 603669 capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Lionco Pharm Grp Co Ltd Market Cap History: 2015 to 2026
Lionco Pharm Grp Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.09 Billion to $561.83 Million (-4.57% CAGR).
Lionco Pharm Grp Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lionco Pharm Grp Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.47x
Lionco Pharm Grp Co Ltd's market cap is 1.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $954.97 Million | $478.59 Million | $153.93 Million | 2.00x | 6.20x |
| 2017 | $632.84 Million | $1.01 Billion | $161.01 Million | 0.63x | 3.93x |
| 2018 | $455.14 Million | $1.67 Billion | $182.70 Million | 0.27x | 2.49x |
| 2019 | $512.36 Million | $1.64 Billion | $201.59 Million | 0.31x | 2.54x |
| 2020 | $865.30 Million | $1.00 Billion | $160.07 Million | 0.86x | 5.41x |
| 2021 | $1.03 Billion | $740.33 Million | $65.90 Million | 1.39x | 15.56x |
| 2022 | $598.32 Million | $289.26 Million | -$195.86 Million | 2.07x | N/A |
| 2023 | $576.43 Million | $196.83 Million | -$151.50 Million | 2.93x | N/A |
| 2024 | $547.24 Million | $379.78 Million | -$130.76 Million | 1.44x | N/A |
| 2025 | $475.32 Million | $322.48 Million | -$193.24 Million | 1.47x | N/A |
Competitor Companies of 603669 by Market Capitalization
Companies near Lionco Pharm Grp Co Ltd in the global market cap rankings as of August 1, 2026.
Key companies related to Lionco Pharm Grp Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #503 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #528 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.48 Billion | CN¥54.08 |
| #550 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.60 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €15.50 |
Lionco Pharm Grp Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Lionco Pharm Grp Co Ltd's market cap moved from $1.09 Billion to $ 561.83 Million, with a yearly change of -4.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥561.83 Million | +18.20% |
| 2025 | CN¥475.32 Million | -13.14% |
| 2024 | CN¥547.24 Million | -5.06% |
| 2023 | CN¥576.43 Million | -3.66% |
| 2022 | CN¥598.32 Million | -41.66% |
| 2021 | CN¥1.03 Billion | +18.53% |
| 2020 | CN¥865.30 Million | +68.88% |
| 2019 | CN¥512.36 Million | +12.57% |
| 2018 | CN¥455.14 Million | -28.08% |
| 2017 | CN¥632.84 Million | -33.73% |
| 2016 | CN¥954.97 Million | -12.70% |
| 2015 | CN¥1.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Lionco Pharm Grp Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $561.83 Million USD |
| MoneyControl | $561.83 Million USD |
| MarketWatch | $561.83 Million USD |
| marketcap.company | $561.83 Million USD |
| Reuters | $561.83 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, and other applications. The company was founded in 2003 a… Read more